5-MeO-DMT Therapy: What the Research Shows and Why Risks Are Real
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the...
Psilocybin OCD Treatment: What the Early Research Shows
Psilocybin OCD treatment is a small but growing area of clinical research, with early data suggesting meaningful symptom reductions for people who have not responded to...
Psychedelic Therapy Contraindications: Who Should Pause First
Psychedelic therapy contraindications include a personal history of psychosis or mania, current lithium use, certain cardiac conditions, and active suicidal ideation with intent. Some of these...
Executive Burnout Psychedelic Therapy: What the Research Shows
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
Psychedelics for Depression: What the 2026 Research Actually Shows
Quick Answer Psilocybin and other psychedelics show real, measurable promise for depression, particularly treatment-resistant cases. But the evidence in 2026 is more complicated, more honest, and...
Microdosing Psychedelics — Promise, Risks, and Where We Go from Here
Quick answer: Microdosing psychedelics means taking very small, sub-perceptual doses of substances such as psilocybin or LSD, usually on a repeated schedule rather than in a...
LSD for Anxiety: What a Landmark Clinical Trial Actually Found
Quick answer: A LSD For Anxiety randomized, placebo-controlled Phase 2b trial published in JAMA found that a single oral dose of MM120, an investigational LSD formulation...
MDMA Therapy FDA Decision, What the Rejection Letter Means for Seekers
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, citing three specific concerns: gaps in safety reporting, insufficient evidence that benefits lasted over time,...
Can Psilocybin Slow Aging? A New Study Hints at What’s Possible
A peer-reviewed study in npj Aging found that psilocybin and aging may be more connected than previously assumed, after treated female mice showed reduced oxidative stress,...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.